Abstract
Background: Ototoxicity is a common disabling side effect of
platinum-based chemotherapy. This study aimed to systematically assess
the evidence on the management of platinum-induced ototoxicity in adult
cancer patients.
Methods: Three databases were searched up to November 1, 2022.
Original studies were included if they reported on a pharmacologic or
non-pharmacologic intervention to prevent or treat platinum ototoxicity
in adults. The articles’ quality was assessed with two grading scales.
Results: Eighteen randomized controlled trials and five
quasi-experimental studies with 1673 patients were analyzed. Eleven
interventions were identified, nine pharmacological and two
non-pharmacological. Six of the interventions (sodium thiosulfate,
corticoids, sertraline, statins, multivitamins, and D-methionine) showed
mild benefit preventing cisplatin-induced ototoxicity. The data must be
carefully analyzed due to the low quality and underreporting of side
effects.
Conclusions: Current interventions have mild benefits
preventing cisplatin-induced ototoxicity in adult cancer patients.
High-quality research is required to clarify the significance of these
findings.
Keywords: Cisplatin-induced ototoxicity, platinum chemotherapy,
chemotherapy-related adverse events, hearing loss, otoprotection.